MedPath

Furosemide

Generic Name
Furosemide
Brand Names
Furoscix, Lasix
Drug Type
Small Molecule
Chemical Formula
C12H11ClN2O5S
CAS Number
54-31-9
Unique Ingredient Identifier
7LXU5N7ZO5

Overview

Furosemide is a potent loop diuretic that acts on the kidneys to ultimately increase water loss from the body. It is an anthranilic acid derivative. Furosemide is used for edema secondary to various clinical conditions, such as congestive heart failure exacerbation, liver failure, renal failure, and high blood pressure. It mainly works by inhibiting electrolyte reabsorption from the kidneys and enhancing the excretion of water from the body. Furosemide has a fast onset and short duration of action and has been used safely and effectively in both pediatric and adult patients. The use of furosemide is particularly beneficial in clinical settings that require a drug with a higher diuretic potential. In addition to oral formulations, the solution for intravenous and intramuscular administration is also available, which is typically limited to patients who are unable to take oral medication or for patients in emergency clinical situations.

Indication

Furosemide is indicated for the treatment of edema associated with congestive heart failure, cirrhosis of the liver, and renal disease, including the nephrotic syndrome, in adults and pediatric patients. Oral furosemide is indicated alone for the management of mild to moderate hypertension or severe hypertension in combination with other antihypertensive medications. Intravenous furosemide is indicated as adjunctive therapy in acute pulmonary edema when a rapid onset of diuresis is desired. Subcutaneous furosemide is indicated for the treatment of congestion due to fluid overload in adults with NYHA Class II/III chronic heart failure. This drug formulation is not indicated for emergency situations or in patients with acute pulmonary edema.

Associated Conditions

  • Acute Pulmonary Edema
  • Ascites
  • Body Fluid Retention
  • Edema
  • Hypertension
  • Mild to Moderate Hypertension
  • Chest congestion

Research Report

Published: Jul 24, 2025

Furosemide (DB00695): A Comprehensive Clinical and Pharmacological Monograph

Drug Identification and Physicochemical Properties

Overview and Nomenclature

Furosemide is a potent, small-molecule loop diuretic that serves as a cornerstone in the management of fluid overload and hypertension.[1] Chemically classified as an anthranilic acid derivative, its primary therapeutic action is achieved through the inhibition of the sodium-potassium-chloride symporter (NKCC), a mechanism that places it in the class of NKCC inhibitors.[1] It is also categorized as an antihypertensive agent.[1]

The drug is universally recognized by its generic name, Furosemide, which is the recommended International Non-Proprietary Name (rINN).[5] An alternative name, Frusemide, was historically the British Approved Name and is still found in use in some regions.[3] Commercially, Furosemide is most famously known by the brand name Lasix, a name anecdotally derived from its typical duration of action, which "lasts six" hours.[1] Other notable brand names include Furoscix and Salix.[1] In major markets such as the United Kingdom and the United States, Furosemide is available by prescription only.[8]

Regulatory and Chemical Identifiers

To ensure unambiguous identification in clinical, research, and regulatory contexts, Furosemide is assigned a comprehensive set of identifiers. These standardized codes and names are essential for accurate data retrieval, reporting, and global pharmacovigilance.

Continue reading the full research report

Clinical Trials

Title
Posted
Study ID
Phase
Status
Sponsor
2025/09/15
Not Applicable
Completed
Bial - Portela C S.A.
2025/09/11
Not Applicable
ENROLLING_BY_INVITATION
2025/04/23
Phase 3
Not yet recruiting
Stacy Johnson
2025/03/27
Phase 3
Recruiting
2025/03/27
Phase 1
Recruiting
2025/02/12
Early Phase 1
ENROLLING_BY_INVITATION
2025/01/22
Not Applicable
ENROLLING_BY_INVITATION
2024/07/17
Phase 1
Completed
2024/06/21
Not Applicable
Recruiting
National Aeronautics and Space Administration (NASA)
2024/06/04
Phase 4
Not yet recruiting

FDA Drug Approvals

Approved Product
Manufacturer
NDC Code
Route
Strength
Effective Date
Baxter Healthcare Corporation
36000-064
INTRAVENOUS
10 mg in 1 mL
10/27/2018
A-S Medication Solutions
50090-6219
ORAL
20 mg in 1 1
7/14/2017
Physicians Total Care, Inc.
54868-2299
INTRAVENOUS
10 mg in 1 mL
3/1/2012
State of Florida DOH Central Pharmacy
53808-0367
ORAL
20 mg in 1 1
6/2/2010
RedPharm Drug, Inc.
67296-0691
ORAL
20 mg in 1 1
1/13/2021
Bryant Ranch Prepack
63629-1120
ORAL
80 mg in 1 1
7/30/2020
NorthStar Rx LLC
72603-133
INTRAVENOUS
10 mg in 1 mL
12/27/2022
Sagent Pharmaceuticals
25021-320
INTRAVENOUS, INTRAMUSCULAR
10 mg in 1 mL
6/26/2025
A-S Medication Solutions
50090-2560
ORAL
20 mg in 1 1
6/28/2018
Major Pharmaceuticals
0904-7178
ORAL
40 mg in 1 1
12/30/2021

EMA Drug Approvals

Approved Product
Authorization Holder
Status
Issued Date
No EMA approvals found for this drug.

HSA Drug Approvals

Approved Product
Manufacturer
Approval Number
Dosage Form
Strength
Approval Date
APO-FUROSEMIDE TABLET 40 mg
SIN00088P
TABLET
40 mg
3/14/1988
FUROSEMIDE-AFT SOLUTION FOR INJECTION 20MG/2ML
SIN16784P
INJECTION, SOLUTION
20mg/2ml
5/16/2023
FUROSEMIDE-BAXTER SOLUTION FOR INJECTION 20 MG/2 ML
SIN15366P
INJECTION, SOLUTION
20 mg/2 mL
11/23/2017
RASITOL TABLET 40MG
SIN14074P
TABLET
40mg
1/9/2012
DIRINE INJECTION 20 mg/2 ml
ATLANTIC LABORATORIES CORPN LTD
SIN00239P
INJECTION
20 mg/2 ml
4/5/1988
FUROSEMIDE-BAXTER SOLUTION FOR INJECTION 50 MG/5 ML
SIN15365P
INJECTION, SOLUTION
50 mg/5 mL
11/23/2017
FUSETIC SOLUTION FOR INJECTION 20MG/2ML
SIN16712P
INJECTION, SOLUTION
20mg/2ml
2/23/2023
LASIX TABLET 40 mg
SIN00199P
TABLET
40.00 mg
3/28/1988
FUROSEMIDE FRESENIUS KABI SOLUTION FOR INJECTION 20MG/2ML
SIN15131P
INJECTION, SOLUTION
20mg/2ml
12/7/2016
FURMIDE TABLETS 40 mg
SIN00064P
TABLET
40.00 mg
2/24/1988

NMPA Drug Approvals

Approved Product
Company
Approval Number
Drug Type
Dosage Form
Approval Date
No NMPA approvals found for this drug.

PPB Drug Approvals

Approved Product
Registration No.
Company
Licence No.
Strength
Registration Date
FUROSEMIDE TABLETS BP 40MG
N/A
N/A
N/A
10/5/2020
FUROSEMIDE-HAMELN SOLUTION FOR INJECTION 20MG/2ML
N/A
N/A
N/A
5/27/2025

Health Canada Drug Approvals

Approved Product
Company
DIN
Dosage Form
Strength
Market Date
APO-FUROSEMIDE
00707570
Tablet - Oral
80 MG
12/31/1986
NU-FUROSEMIDE TABLETS
nu-pharm inc
02239226
Tablet - Oral
80 MG
N/A
FUROSEMIDE INJECTION USP
hikma canada limited
02384094
Solution - Intravenous ,  Intramuscular
20 MG / 2 ML
8/22/2013
NU-FUROSEMIDE TABLETS
nu-pharm inc
02239225
Tablet - Oral
40 MG
3/19/2004
MINT-FUROSEMIDE
mint pharmaceuticals inc
02466775
Tablet - Oral
80 MG
7/30/2018
PMS-FUROSEMIDE
02247493
Tablet - Oral
20 MG
12/10/2003
LASIX
sanofi-aventis canada inc
02224690
Tablet - Oral
20 MG
4/21/1997
FUROSEMIDE
sanis health inc
02351420
Tablet - Oral
20 MG
6/15/2010
BIO-FUROSEMIDE
biomed pharma
02247371
Tablet - Oral
20 MG
4/11/2003
LASIX SPECIAL TABLETS 500MG
hoechst roussel canada inc.
01987615
Tablet - Oral
500 MG
12/31/1994

CIMA AEMPS Drug Approvals

Approved Product
Company
Registration Number
Pharmaceutical Form
Prescription Type
Status
FUROSEMIDA NORMON 40 MG COMPRIMIDOS EFG
Laboratorios Normon S.A.
85062
COMPRIMIDO
Medicamento Sujeto A Prescripción Médica. Tratamiento De Larga Duración
Not Commercialized
FUROSEMIDA ALTAN 250mg/ 25ml SOLUCION PARA PERFUSION EFG
Altan Pharmaceuticals Sa
68258
SOLUCIÓN PARA PERFUSIÓN
Uso Hospitalario
Commercialized
FUROSEMIDA SALA 20 mg/2 ml SOLUCION INYECTABLE EFG
Laboratorio Reig Jofre, S.A.
65540
SOLUCIÓN INYECTABLE
Medicamento Sujeto A Prescripción Médica
Not Commercialized
FUROSEMIDA BEXAL 40 mg COMPRIMIDOS EFG
Bexal Farmaceutica S.A.
68078
COMPRIMIDO
Medicamento Sujeto A Prescripción Médica. Tratamiento De Larga Duración
Not Commercialized
FUROSEMIDA CINFA 40 mg COMPRIMIDOS EFG
Laboratorios Cinfa S.A.
64140
COMPRIMIDO
Medicamento Sujeto A Prescripción Médica. Tratamiento De Larga Duración
Commercialized
FUROSEMIDA UXA 40 MG COMPRIMIDOS EFG
Uxa Farma S.A.
79029
COMPRIMIDO
Medicamento Sujeto A Prescripción Médica. Tratamiento De Larga Duración
Commercialized
FUROSEMIDA PHYSAN 20mg/2ml SOLUCIÓN INYECTABLE EFG
Laphysan S.A.U.
62168
SOLUCIÓN INYECTABLE
Medicamento Sujeto A Prescripción Médica
Commercialized
FUROSEMIDA TECNIGEN 40 MG COMPRIMIDOS EFG
Tecnimede España Industria Farmaceutica S.A.
86391
COMPRIMIDO
Medicamento Sujeto A Prescripción Médica. Tratamiento De Larga Duración
Not Commercialized
FUROSEMIDA ALTAN 20mg/2ml SOLUCION INYECTABLE EFG
Altan Pharmaceuticals Sa
68257
SOLUCIÓN INYECTABLE
Uso Hospitalario
Not Commercialized
FUROSEMIDA REIG JOFRE 20 mg/2 ml SOLUCION INYECTABLE EFG
Laboratorio Reig Jofre, S.A.
65486
SOLUCIÓN INYECTABLE
Medicamento Sujeto A Prescripción Médica
Not Commercialized

Philippines FDA Drug Approvals

Approved Product
Company
License Number
Dosage Form
Strength
Approval Date
No Philippines FDA approvals found for this drug.

Saudi SFDA Drug Approvals

Approved Product
Company
License Number
Dosage Form
Strength
Approval Date
No Saudi SFDA approvals found for this drug.

Malaysia NPRA Drug Approvals

Approved Product
Company
Registration Number
Dosage Form
Strength
Approval Date
No Malaysia NPRA approvals found for this drug.

UK EMC Drug Information

Medicine Name
MA Holder
MA Number
Pharmaceutical Form
Active Ingredient
Authorization Date
No UK EMC drug information found for this drug.

Help Us Improve

Your feedback helps us provide better drug information and insights.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.